Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03117036 |
Recruitment Status :
Recruiting
First Posted : April 17, 2017
Last Update Posted : November 27, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Lymphoma, Non-Hodgkin Lymphoma, Hodgkin | Drug: Chemotherapy |
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.
- Registration after informed consent.
- Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood
- Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood
- Regular monitoring disease status and update of survival status
- Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 600 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 3 Years |
Official Title: | A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center |
Actual Study Start Date : | March 1, 2017 |
Estimated Primary Completion Date : | December 28, 2024 |
Estimated Study Completion Date : | December 28, 2026 |
Group/Cohort | Intervention/treatment |
---|---|
Lymphoma
Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
|
Drug: Chemotherapy
Systemic chemotherapy with curative intent
Other Name: Treatment |
- Response rate [ Time Frame: 3 months after chemotherapy ]response to chemotherapy
- Progression-free survival [ Time Frame: 3 year ]Time to relapse/progression or any kinds of death
- Overall survival [ Time Frame: 3 year ]Time to any kinds of death
- Biomarker [ Time Frame: 3 year ]Development of biomarker predicting response and survival outcome
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- 20 years
- Patients requiring systemic chemotherapy with curative intent
- Written informed consent
Exclusion Criteria:
- Myeloid malignancy
- Multiple myeloma
- Patients do not require systemic chemotherapy with curative intent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03117036
Contact: Seok Jin Kim, MD, PhD | +82234101766 | kstwoh@skku.edu |
Korea, Republic of | |
Samsung Medical Center | Recruiting |
Seoul, Korea, Republic of, 135-710 | |
Contact: Seok Jin Kim, MD, PhD 82-2-3410-1766 kstwoh@skku.edu | |
Principal Investigator: Seok Jin Kim, MD, PhD | |
Sub-Investigator: Won Seog Kim, MD, PhD | |
Sub-Investigator: Sivia Park, MD, PhD |
Principal Investigator: | Seok Jin Kim, MD, PhD | Samsung Medical Center |
Responsible Party: | Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT03117036 |
Other Study ID Numbers: |
2016-11-040 |
First Posted: | April 17, 2017 Key Record Dates |
Last Update Posted: | November 27, 2023 |
Last Verified: | November 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
lymphoma cohort serum cell-free DNA |
Lymphoma Lymphoma, Non-Hodgkin Hodgkin Disease Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |